SLG
MRSN

Stanley-Laman Group’s Mersana Therapeutics MRSN Stock Holding History

Stanley-Laman Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-710
Closed -$280K – 270
2018
Q1 		$280K Buy
+710
New +$280K 0.06% 242

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Stanley-Laman Group's MRSN Position: Q2 2018 in Review

Stanley-Laman Group sold out of Mersana Therapeutics (MRSN) in Q2 2018, closing a stake of 710 shares — an estimated $280K sold.

Stanley-Laman Group first reported a position in MRSN in Q1 2018 and held it in 1 quarter. The position peaked at $280K in Q1 2018. 53 funds tracked by Wall St. Rank hold MRSN as of Q2 2018.

  • Stanley-Laman Group reported no remaining Mersana Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 710 Mersana Therapeutics shares in Q2 2018, an estimated $280K.
  • Stanley-Laman Group first reported a position in Mersana Therapeutics in Q1 2018 and held it in 1 quarter.
  • Stanley-Laman Group's Mersana Therapeutics position peaked at $280K in Q1 2018.
  • 53 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2018.

Based on Stanley-Laman Group's 13F filing for Q2 2018, filed 9 Aug 2018.